Market Access Archives

Blog

‘Most Favored Nation’ 政策若全面实施或对全球药品定价产生深远影响

Editor’s Note: Jiwon Oh provided research support for this article. She is a Certara Market…

Certara2025 年 5 月 23 日

White Paper

ILAP 2.0 核心要点全解析

This white paper share’s key insights on the relaunch of MHRA’s Innovative Licensing and Access…

Certara2025 年 5 月 19 日

Brochure

确立并宣传医疗保健产品的价值

Certara2024 年 10 月 9 日

Case Study

联合临床评估（JCA）及其对基因疗法评估的潜在影响

In October 2019, Galderma announced that the U.S. FDA approved AKLIEF® (trifarotene) Cream, 0.005% for the…

Certara2024 年 6 月 17 日

Case Study

利用价值传播技术和综合工作流程加快药品上市速度

With early approvals for a targeted cancer drug in Brazil and Argentina, this global pharmaceutical…

Certara2023 年 10 月 2 日

Case Study

Using customer engagement technology to create value communication tools for ABILIFY MAINTENA® (aripiprazole)

Otsuka identified several weaknesses in their existing workflow for developing value communication tools. In particular,…

Certara2023 年 10 月 2 日

Case Study

Using Real-World Evidence to Derive an External Control Arm for a Rare Disease Drug Trial

Our client was developing a new anti-viral drug for a rare, life-threatening viral infection that…

Certara2023 年 4 月 17 日

Case Study

运用真实世界证据指导治疗指南制定

Real-World Evidence (RWE) has become increasingly valuable in informing the development of treatment guidelines for…

Certara2023 年 4 月 5 日

Case Study

Using Real Word Evidence to Enhance Drug Development

Real-world evidence (RWE) has emerged as an increasingly important tool in the drug development process,1…

Certara2023 年 4 月 5 日

Case Study

基于主体的模型可预测大流行期间单克隆抗体治疗、预防和疫苗对病毒传播的影响

Agent-based models focus on the heterogeneous behavior of individual agents and their interactions with one…

Certara2023 年 3 月 2 日

市场准入

‘Most Favored Nation’ 政策若全面实施或对全球药品定价产生深远影响

ILAP 2.0 核心要点全解析

确立并宣传医疗保健产品的价值

联合临床评估（JCA）及其对基因疗法评估的潜在影响

利用价值传播技术和综合工作流程加快药品上市速度

Using customer engagement technology to create value communication tools for ABILIFY MAINTENA® (aripiprazole)

Using Real-World Evidence to Derive an External Control Arm for a Rare Disease Drug Trial

运用真实世界证据指导治疗指南制定

Using Real Word Evidence to Enhance Drug Development

基于主体的模型可预测大流行期间单克隆抗体治疗、预防和疫苗对病毒传播的影响

订阅时事通讯

快捷链接

解决方案

联系我们